|drug1009||Decidual Stromal Cells (DSC) Wiki||0.58|
|drug284||Apixaban 5MG Wiki||0.58|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.05|
|D055371||Acute Lung Injury NIH||0.05|
There are 3 clinical trials
ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19.
Description: composite of hospitalization or deathMeasure: Outpatient trial - Colchicine vs. control and Aspirin vs. control Time: 45 days post randomization
Description: invasive mechanical ventilation or deathMeasure: Inpatient trial - Interferon-β vs. control and Colchicine vs. control Time: 45 days post randomization
Description: invasive mechanical ventilation or deathMeasure: Inpatient trial - Aspirin and rivaroxaban vs. control Time: 45 days post randomization
Description: disease progression by 2 points on a 7-point scaleMeasure: Outpatient and Inpatient trials - Colchicine vs. control, Interferon-β vs. control Time: 45 days post randomization
Description: composite of major adverse cardiovascular events (MI, stroke, ALI, VTE, death), and disease progression by 2 points on a 7-point scaleMeasure: Outpatient and Inpatient trials - Aspirin vs. control, Aspirin and rivaroxaban vs. control Time: 45 days post randomization
The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.
Description: Cause of death will be describedMeasure: Death Time: up to 28 days of randomisation
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
Description: The primary outcome will be a composite endpoint of need for hospitalization for cardiovascular/pulmonary events, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, ischemic stroke, and all-cause mortality for up to 45 days after initiation of assigned treatment.Measure: Primary Time: 45 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports